Pulmonary Combined Large Cell Neuroendocrine Carcinoma

Li, Meihui; Yang, Lan; Lu, Hongyang

doi:10.3389/pore.2022.1610747

Cited by 4 publications

(2 citation statements)

References 41 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The corresponding PFS times were 9.47, 6.00, and 3.73 months. Therefore, we propose the potential for greater benefit of ICIs to c-LCNEC, which may be related to the high tumor mutational burden ( 33 ) and the distinct biological characteristics of combined components, but more clinical evidence is still needed.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

Shi,

Wei,

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

Background Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare and highly aggressive neuroendocrine tumor. There is currently no standard therapeutic regimen, and systemic chemotherapy results in poor prognosis. Due to the rarity of L-LCNEC, the efficacy and safety of immune checkpoint inhibitors (ICIs) remain unclear. Methods This study included 34 L-LCNEC patients administered ICIs at Zhejiang Cancer Hospital, from February 6, 2018 to February 6, 2023. The treatment responses were evaluated. Fisher’s exact test was used to compare categorical variables, and the Kaplan-Meier method was used for survival analyses. Cox regression was used for multivariate analysis. Results The objective response rate (ORR) of 34 patients was 29.4%, the disease control rate (DCR) was 82.4%, the median progression-free survival (PFS) was 6.30 months, and the median overall survival (OS) was 14.77 months. The ORRs of combined LCNEC (n=7) and pure LCNEC (n=27) were 14.3% and 33.3%; the DCRs were 100% and 77.8%; the median PFSs were 12.48 and 5.6 months (P=0.032); and the median OSs were 21.27 and 14.73 months, respectively (P=0.233). The observed incidence of immune-related adverse events (irAEs) was 61.8%, primarily occurring in grades 1/2 (58.8%) and grade 3 (5.9%). Elevated aminotransferases (14.7%), pneumonia (8.8%), and fatigue (8.8%) were the most common irAEs. Conclusions ICIs treatment showed efficacy and safety in advanced L-LCNEC, with the potential for greater benefits in the combined LCNEC subtype.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of immune checkpoint inhibitors in lung large-cell neuroendocrine carcinoma

Shi,

Wei,

et al. 2023

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Nevertheless, immunotherapy rarely provides benefits when combined with LCNC treatment. Further research should be done [ 41 ].…”

Section: Introductionmentioning

confidence: 99%

Advances in combined neuroendocrine carcinoma of lung cancer

Han,

Yang,

Wang

et al. 2024

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Lung cancer incidence and mortality rates are increasing worldwide, posing a significant public health challenge and an immense burden to affected families. Lung cancer encompasses distinct subtypes, namely, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). In clinical investigations, researchers have observed that neuroendocrine tumors can be classified into four types: typical carcinoid, atypical carcinoid, small-cell carcinoma, and large-cell neuroendocrine carcinoma based on their unique features. However, there exist combined forms of neuroendocrine cancer. This study focuses specifically on combined pulmonary carcinomas with a neuroendocrine component. In this comprehensive review article, the authors provide an overview of combined lung cancers and present two pathological images to visually depict these distinctive subtypes.

show abstract